 TUCSON, Ariz., Nov. 02, 2020 GLOBE NEWSWIRE -- HTG Molecular Diagnostics, Inc. Nasdaq: HTGM HTG, a life science company whose mission is to advance precision medicine, today announced the completion of proof of concept for a whole transcriptome panel using the HTG EdgeSeq technology, and release of a White Paper illustrating the feasibility and performance of this prototype panel relative to RNA sequencing RNA-Seq. As previously discussed, HTG is developing a whole transcriptome panel utilizing the HTG EdgeSeq technology to measure approximately 20,000 mRNA targets, with a planned RUO launch in mid-2021. 